Introduction
============

Ovarian cancer (OC) shows the highest cancer-related death rate among gynecological malignancies, with an estimated 204,000 cases and 125,000 deaths annually worldwide.[@b1-cmar-10-6937],[@b2-cmar-10-6937] Over 75% of patients are not diagnosed until the disease is advanced (stages III and IV). Current prognostic factors do not allow reliable prediction of response to chemotherapy and survival for individual OC patients. The poor rate of survival and the high rate of lethality are partly due to lack of effective biomarkers for prognosis. Therefore, there is a pressing need to find reliable predictive biomarkers for prognosis and to develop novel therapeutic strategies for OC patients.[@b2-cmar-10-6937],[@b3-cmar-10-6937]

The epidermal growth factor receptor (*EGFR*) tyrosine kinase family consists of four members: *EGFR*, *ERBB2*, *ERBB3*, and *ERBB4*. These receptors are activated when a ligand binds to their extracellular ligand binding domain, which triggers receptor homodimerization or heterodimerization, resulting in the activation of several downstream cell signaling pathways and ultimately in tumor cell proliferation, reduced apoptosis, and tumor migration and invasion.[@b4-cmar-10-6937]--[@b6-cmar-10-6937] In the past three decades, increased aberrant expression or activation of the *EGFR* family members has been reported in a wide range of cancers, and in some studies, has also been associated with poor prognosis and resistance to therapeutic options.[@b5-cmar-10-6937],[@b7-cmar-10-6937] Moreover, the *EGFR* family of tyrosine kinases has emerged as an important therapeutic target in malignancies, and to date, numerous antibodies, recombinant proteins, peptide mimetics, and small molecules, such as cetuximab, panitumumab, trastuzumab, gefitinib, erlotinib, and lapatinib, have been developed for targeting *EGFR* family receptors as therapeutic targets for many kinds of solid tumors.[@b4-cmar-10-6937],[@b7-cmar-10-6937] Recent reports have suggested that the functions of different EGFR members contribute to OC tumorigenesis. However, the clinicopathological and prognostic value and expression patterns of *EGFR* family members in OC remain controversial.[@b8-cmar-10-6937]--[@b10-cmar-10-6937] In addition, the role of *EGFR* family members in OC and the underlying molecular mechanism responsible for its involvement in tumor development and progression are largely unknown.

The development of microarray and RNA-sequencing technology has revolutionized RNA and DNA research, which has become a crucial component of biology and biomedical research.[@b11-cmar-10-6937],[@b12-cmar-10-6937] In the current study, we extended the knowledge base related to OC based on a variety of large databases, with the purpose of determining the expression patterns, genetic alteration, potential functions, and distinct prognostic values of *EGFR* family members in OC.

Materials and methods
=====================

Ethics statement
----------------

This study was approved by the Academic Committee of the People's Hospital of China Three Gorges University, and conducted according to the principles expressed in the Declaration of Helsinki. All the datasets were retrieved from the databases, so it was confirmed that written informed consent had been obtained from all patients.

ONCOMINE analysis
-----------------

The gene expression array datasets of ONCOMINE ([www.oncomine.org](http://www.oncomine.org)), which is a publicly accessible, online cancer microarray database helps facilitate research data from genome-wide expression analyses. ONCOMINE was used to analyze the mRNA levels of *EGFR* family members in OC.[@b13-cmar-10-6937],[@b14-cmar-10-6937] In this study, the Student's *t*-test was used to generate *P*-values for comparison between cancer specimens and normal control datasets. The cutoff *P*-value and fold change were defined as 0.05 and 1, respectively.

Gene Expression Profiling Interactive Analysis (GEPIA) dataset analysis
-----------------------------------------------------------------------

GEPIA is an interactive web server for estimating mRNA expression data based on 9,736 tumors and 8,587 normal samples in The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression dataset projects. GEPIA provides key interactive and customizable functions including differential expression analysis, profiling plotting, correlation analysis, patient survival analysis, similar gene detection, and dimensionality reduction analysis.[@b15-cmar-10-6937]

The Kaplan--Meier plotter analysis
----------------------------------

The prognostic value of the mRNA expression of *EGFR* family members was evaluated using an online database, Kaplan--Meier Plotter ([www.kmplot.com](http://www.kmplot.com)), which contains gene expression data and survival information of 1,816 clinical OC patients. To analyze the overall survival (OS), progression-free survival (PFS), and post-progression survival (PPS) of patients with OC, patient samples were split into two groups by median expression (high vs low expression) and assessed by a Kaplan--Meier survival plot, with a HR with 95% CI and log-rank *P*-value.[@b16-cmar-10-6937]

TCGA and CBioPortal analysis
----------------------------

Gene alteration frequency of EGFR family member mRNA in OC was performed using CBioPortal for Cancer Genomics (<http://www.cbioportal.org>). The genomic profiles included mutations, putative copy-number alterations from GISTIC, mRNA expression z scores, and protein expression z scores.[@b17-cmar-10-6937]

Functional enrichment and bioinformatics analysis
-------------------------------------------------

GeneMANIA (<http://www.genemania.org>) is a flexible, user-friendly web interface for generating hypotheses about gene function, analyzing gene lists, and prioritizing genes for functional assays. GeneMANIA was used to conduct correlation analysis of EGFR family members at the gene level, which revealed relationships in pathways, shared protein domains, co-localization, and co-expression.[@b18-cmar-10-6937] Finally, enrichment analysis was performed with The Database for Annotation, Visualization and Integrated Discovery (DAVID) (version 6.7) for *EGFR* family members and their neighboring genes. DAVID includes the gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.[@b19-cmar-10-6937],[@b20-cmar-10-6937]

Results
=======

Transcription levels of *EGFR* family members in patients with OC
-----------------------------------------------------------------

Using ONCOMINE analysis, four *EGFR* family members have been identified in human cancers, including hematological malignancies and solid tumors ([Figure 1](#f1-cmar-10-6937){ref-type="fig"}). ONCOMINE analysis revealed that the mRNA expression levels of *ERBB3* were significantly upregulated in patients with OC in three datasets. In Hendrix's dataset,[@b21-cmar-10-6937] *ERBB3* is overexpressed compared with that in the normal samples in all OC types -- ovarian mucinous adenocarcinoma with a fold change of 2.355, ovarian clear cell adenocarcinoma with a fold change of 2.308, ovarian endometrioid adenocarcinoma with a fold change of 1.897, and ovarian serous adenocarcinoma with a fold change of 1.857. In Adib's dataset,[@b22-cmar-10-6937] *ERBB3* is overexpressed in ovarian serous adenocarcinoma with a fold change of 1.807. In Lu's dataset,[@b23-cmar-10-6937] *ERBB3* is overexpressed in ovarian endometrioid adenocarcinoma with a fold change of 1.635 and in ovarian serous adenocarcinoma with a fold change of 1.947 compared with that in the normal samples. The transcription levels of *EGFR* in ovarian serous adenocarcinoma were lower than that in normal ovarian tissues in two datasets (fold changes were −1.223 and −1.349, respectively)[@b22-cmar-10-6937],[@b24-cmar-10-6937] ([Table 1](#t1-cmar-10-6937){ref-type="table"}).

As shown in [Table 1](#t1-cmar-10-6937){ref-type="table"}, the transcription levels of *ERBB2* and *ERBB4* in different pathological types of OC (eg, ovarian endometrioid adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian serous adenocarcinoma, ovarian clear cell adenocarcinoma, ovarian serous surface papillary carcinoma, ovarian serous adenocarcinoma, and ovarian carcinoma) were also slightly higher than those in normal ovarian tissues, and their cutoff of *P*-value was \>0.05.

In addition, using the GEPIA dataset (<http://gepia.cancer-pku.cn/>), we compared the mRNA expression of EGFR family members between OC and normal tissues. The results demonstrated that the mRNA expression levels of *ERBB3* and *ERBB4* were significantly higher in OC tissues than in normal ovarian tissues, whereas the expression level of *EGFR* was significantly lower in the former than in the latter. We also analyzed the expression of EGFR family members in different tumor stages of OC. None of the EGFR family members varied in the different tumor stages ([Figure 2](#f2-cmar-10-6937){ref-type="fig"}).

Prognostic values of *EGFR* family members in all patients with OC
------------------------------------------------------------------

Using Kaplan--Meier plotter analysis, we initially assessed the prognostic significance of the *EGFR* family members in all OC patients. The Kaplan--Meier survival curves are demonstrated in [Figure 3](#f3-cmar-10-6937){ref-type="fig"}. The increased *EGFR* mRNA level and the decreased *ERBB2* and *ERBB3* mRNA levels were strongly associated with the poor OS. However, high mRNA levels of *EGFR* or low mRNA levels of *ERBB4* were predicted to have high *PFS*. In addition, the mRNA expression levels of *EGFR*, *ERBB2*, *ERBB3*, and *ERBB4* were not correlated with PPS of all patients with OC.

The prognostic value of EGFR family members was assessed in different pathological histology subtypes of OC, including serous and endometrioid. As shown in [Table 2](#t2-cmar-10-6937){ref-type="table"}, high *ERBB2* mRNA expression was correlated to longer OS in serous OC patients. The mRNA expression levels of *EGFR* and *ERBB4* were associated with poor OS in serous OC patients. Increased *EGFR*, *ERBB2*, and *ERBB3* mRNA expression levels were associated with poor *PFS*. In endometrioid OC, high *ERBB4* mRNA expression level was associated with better OS. The rest of the EGFR family members were not related with prognosis in endometrioid OC.

Prognostic values of *EGFR* family members in OC patients with different clinicopathological features
-----------------------------------------------------------------------------------------------------

To further assess the association of individual EGFR family members with other clinicopathological features, we assessed the correlation between them with pathological grades, clinical grades, and TP53 status of OC patients ([Table 3](#t3-cmar-10-6937){ref-type="table"}). As shown in [Table 3](#t3-cmar-10-6937){ref-type="table"}, high mRNA expression of *ERBB4* was associated with better OS and PFS in pathological grade I OC patients. Elevated mRNA expression of *ERBB3* was associated with better OS and PFS in grade II OC patients. In pathological grade III OC patients, high *EGFR* and *ERBB4* mRNA expression was linked to poor OS or PFS, but high *ERBB2* mRNA expression was found to be correlated to longer OS. None of the EGFR family members were related with prognosis in grade IV OC patients. In terms of clinical staging, as we can see from [Table 3](#t3-cmar-10-6937){ref-type="table"}, increased mRNA expression of *ERBB2* and *ERBB4* was associated with longer PFS, but high mRNA expression of *ERBB2* was linked to poor OS in clinical stage I and II patients. For clinical stage III and IV OC patients, high mRNA expression of *EGFR* and *ERBB2* was associated with poor PFS in this subgroup. Additionally, [Table 3](#t3-cmar-10-6937){ref-type="table"} also shows that high mRNA expression levels of *ERBB2* and *ERBB3* were associated with poor OS and PFS, and elevated mRNA expression of *EGFR* was associated with poor PFS in mutated-TP53-type OC. However, high mRNA expression level of *ERBB4* was associated with better PFS in this subgroup.

Genetic alteration and neighbor genes of *EGFR* family members in OC
--------------------------------------------------------------------

We analyzed the genetic alterations of *EGFR* family members by using the cBioPortal online tool for OC. A total of 839 patients from three datasets of ovarian serous cystadenocarcinoma and 12 patients from one dataset of small cell carcinoma were analyzed. Among 4°C datasets analyzed, alterations ranging from 10.3% (58/563) to 13.7% (83/606) were found for the gene sets submitted for analysis ([Figure 4A](#f4-cmar-10-6937){ref-type="fig"}). The percentages of genetic alterations in *EGFR* family members for OC varied from 2.7% to 5.0% for individual genes (*EGFR*, 2.7%; *ERBB2*, 4%; *ERBB3*, 5%; and *ERBB4*, 5%) ([Figure 4B](#f4-cmar-10-6937){ref-type="fig"}). After cBioPortal, Kaplan--Meier plotter and log-rank test, the results indicated that there are no significant difference in OS and disease-free survival (DFS) in cases with or without alterations in one of the *EFGR* family genes (*P*-values, 0.454 and 0.321, respectively) ([Figure 4C, D](#f4-cmar-10-6937){ref-type="fig"}). We then constructed a network for *EGFR* family members with the structure or function of neighboring genes using Gen-eMANIA. The results showed that 20 genes -- *ABL1*, *ABL2*, *ANKS1A*, *ANKS1B*, *BTC*, *CRK*, *EREG*, *GRAP2*, *GRB2*, *GRB7*, *NRG1*, *NRG2*, *PIK3R2*, *PIK3R3*, *PLCG2*, *PTK6*, *SHC1*, *SHC4*, *TGFA*, and *TNS3* -- were closely associated with EGFR family members ([Figure 4E](#f4-cmar-10-6937){ref-type="fig"}). GeneMANIA also was used to conduct correlation analysis of *EGFR* family members at the gene level. There were relationships between *EGFR* and *ERBB2* in co-expression, pathway, physical interactions, and shred protein domains. There were also relationships between *EGFR* and *ERBB3* in pathway, physical interactions, and shred protein domains. There were physical interactions, prediction, and shared protein domains between *EGFR* and *ERBB4*. In addition, there were relationships in co-expression, co-localization, pathway, physical interactions, shared protein domains, and prediction between *ERBB2* and *ERBB3*. There were relationships between EEBB2 and *ERBB4* in pathway, physical interactions, prediction, and shred protein domains. *ERBB3* and *ERBB4* shared physical interactions, prediction, and shred protein domains. Detailed results are presented in [Figure 4E](#f4-cmar-10-6937){ref-type="fig"}.

Significant functions and pathway enrichment analysis of *EGFR* family members in OC
------------------------------------------------------------------------------------

The functions of *EGFR* family members and their neigh-boring genes were predicted by analyzing GO and KEGG in DAVID. Based on DAVID, a total of 58 GO functions were enriched. The enrichment items were classified into three functional groups: biological process (BP) group (10 items), molecular function (MF) group (41 items), and cellular component (CC) group (7 items). As shown in [Table 4](#t4-cmar-10-6937){ref-type="table"}, the *EGFR* family members and their neighboring genes were mainly enriched in the following BP: transmembrane receptor protein tyrosine kinase signaling pathway, EGFR signaling pathway, insulin receptor signaling pathway, positive regulation of cell proliferation, and cell differentiation. The MF that these genes were mainly associated with are receptor binding, non-membrane spanning protein tyrosine kinase activity, manganese ion binding, ATP binding, and receptor tyrosine kinase binding; the CC that these genes were associated with are the extrinsic component of the cytoplasmic side of the plasma membrane, extracellular space, and phosphatidylinositol 3-kinase complex, and the focal adhesion and receptor complex.

Next, 51 pathways related to the functions of *EGFR* family members were found through KEGG analysis. The top ten KEGG pathways for EGFR family members are shown in [Figure 5](#f5-cmar-10-6937){ref-type="fig"}. Among these pathways, the ErbB signaling pathway, neurotrophin signaling pathway, Ras signaling pathway, microRNAs in cancer, proteoglycans in cancer, and focal adhesion were found to be involved in OC tumorigenesis and pathogenesis.

Discussion
==========

Accumulative studies have determined that aberrant expression or activation of the *EGFR* family members is a common feature in human cancers, and the functions of different *EGFR* family members are associated with tumorigenesis and progression of solid tumors.[@b4-cmar-10-6937],[@b5-cmar-10-6937],[@b7-cmar-10-6937],[@b25-cmar-10-6937]--[@b27-cmar-10-6937] However, the patterns of expression and the exact roles the distinct EGFR family members play in contributing to OC are yet to be elucidated.[@b8-cmar-10-6937]--[@b10-cmar-10-6937],[@b28-cmar-10-6937] In the current study, we comprehensively explored the expression patterns, prognostic values (OS, PFS, and PPS), genetic alteration, and potential functions of different *EGFR* family members based on a variety of large databases.

Among the *EGFR* family members, *EGFR* is the most studied in OC since it was first identified in the 1970s.[@b29-cmar-10-6937] Till date, various cancer cells are characterized by *EGFR* hyper-activation, overexpression, or mutants with dysregulated signaling. *EGFR* and its signaling activity have been targets for developing novel therapeutic drugs to treat a variety of cancers.[@b30-cmar-10-6937]--[@b33-cmar-10-6937] Recent studies confirmed that amplification and overexpression of *EGFR* have been reported in several solid cancers, and a growing body of research interests has focused on the prognostic value and therapeutic potential of *EGFR* for OC.[@b8-cmar-10-6937]--[@b10-cmar-10-6937],[@b28-cmar-10-6937] In our study, ONCOMINE and GEPIA datasets revealed that the mRNA expression of *EGFR* was lower in OC than in normal tissues. This inconsistent expression pattern might be because ONCOMINE and GEPIA only represent mRNA data, which only correlate to \~40% of the total protein levels.[@b34-cmar-10-6937] Consistent with the results of most previous studies, our results demonstrated that *EGFR* expression was not correlated with the clinical stage of the patients with OC, and an increased *EGFR* expression was significantly associated with poor OS and PPS in the patients with OC, especially in serous and advanced OC. However, several different studies suggest that *EGFR* is not a reliable marker of survival in OC.[@b29-cmar-10-6937],[@b35-cmar-10-6937],[@b36-cmar-10-6937] The utility of *EGFR* expression as an independent prognostic indicator in OC patients is yet to be confirmed.[@b37-cmar-10-6937],[@b38-cmar-10-6937]

*ERBB2* is a tyrosine kinase receptor in the EGFR family and plays a pivotal role in cell proliferation and tumor cell metastasis.[@b39-cmar-10-6937],[@b40-cmar-10-6937] Previous studies have demonstrated that *ERBB2* overexpression or mutations in human malignant cancers correlate with poor prognosis and chemo-resistance.[@b40-cmar-10-6937]--[@b42-cmar-10-6937] Until now, the association between *ERBB2* expression and OC has been widely studied, however, its relationship with disease stage, grade, and response to treatment remains controversial.[@b43-cmar-10-6937]--[@b45-cmar-10-6937] A recent meta-analysis study showed that *HER2* expression can be used as a prognostic biomarker in OC patients.[@b46-cmar-10-6937] Our results demonstrated that the transcription levels of *ERBB2* in different pathological types of OC were not remarkably higher than those in normal tissues, and increased *ERBB2* mRNA levels were significantly associated with the better OS, especially in clinical stage I and II OC patients. Interestingly, high expression of *ERBB2* was associated with poor PFS in clinical stage III and IV OC patients and with poor OS and PFS in mutated-TP53-type OC patients.

The third member of the *EGFR* family, *ERBB3*, unlike the other EGFR family members that are activated through autophosphorylation upon binding with the ligand, lacks an intracellular tyrosine kinase domain.[@b47-cmar-10-6937] Therefore, *ERBB3* must act as an allosteric activator. It forms heterodimers with other *EGFR* family members, thus stimulating downstream growth and signaling pathways.[@b48-cmar-10-6937] *ERBB3* has been shown to be overexpressed in several human carcinomas, and somatic mutations have been found scattered throughout the *ERBB3* gene in subsets of breast cancers, gastric cancers, and OC.[@b49-cmar-10-6937]--[@b51-cmar-10-6937] In addition, *ERBB3* has been recently characterized as having a significant role in mediating resistance to *EGFR*- and *ERBB2*-directed therapies in solid malignancies, suggesting that *ERBB3* also has a role in mediating resistance to PI3K/AKT pathway inhibitors.[@b48-cmar-10-6937],[@b52-cmar-10-6937],[@b53-cmar-10-6937] Our study showed that the mRNA expression levels of *ERBB3* were considerably upregulated in patients with OC in three datasets, and increased *ERBB3* mRNA levels were associated with the better OS, especially in pathological grade II OC patients. High expression of *ERBB2* was associated with poor PFS in serous OC patients and poor OS and PFS in mutated-*TP53*-type OC patients.

*ERBB4* is one of the four members in the EGFR subfamily of receptor tyrosine kinases. Unlike *ERBB2*, which cannot directly bind a ligand, and *ERBB3*, which does not have a functional kinase domain, *ERBB4* is a fully functional receptor tyrosine kinase capable of signaling, both as a homodimer and as a heterodimer.[@b54-cmar-10-6937] Among different EGFR family members, the role of *ERBB4* in cancer is probably the least understood.[@b55-cmar-10-6937] *ERBB4* is necessary for the development of the heart, mammary gland, and the central nervous system, and mutations in *ERBB4* have been identified in various cancer types including melanoma, lung adenocarcinoma, and medulloblastoma. These results suggest that *ERBB4* can be a potential biomarker for malignant tumors.[@b54-cmar-10-6937],[@b56-cmar-10-6937] Our results showed that increased expression of *ERBB4* might indicate better PFS in all OC patients and longer OS in endometrioid OC patients; however, increased *ERBB4* expression may correlate with worse OS in serous OC patients.

Mutations, gene amplification, and protein overexpression of *EGFR* family members are all linked to carcinogenesis.[@b47-cmar-10-6937] Mutant *EGFR* family members cause a gain-of-function phenotype and are involved in tumorigenesis, invasion, and metastasis.[@b57-cmar-10-6937] In our current analysis, we found that the percentages of alterations in EGFR family members among OC varied from 2.7% to 5.0% for individual genes, but there is no significant difference in OS and DFS in cases with or without alterations in one of the EFGR family genes (*P*-values, 0.454 and 0.321, respectively). To further clarify the carcinogenic mechanism of the EGFR family members, we constructed a network for *EGFR* family members and 20 neighboring genes. The results of GO and KEGG analysis indicated that these genes are mainly enriched in tumor-related pathways, including the ErbB signaling pathway, neurotrophin signaling pathway, and Rams signaling pathway, and in microRNAs and proteoglycans in cancer, and during focal adhesion. Our study adds to the growing evidence regarding the complexity of the *EGFR* family members and their associated signaling pathways, which offer clues into the rational development of dual targeting with anti-EGFR or HER2 and downstream pathway inhibitors.

To the best of our knowledge, this is the first bioinformatics analysis exploring the distinct expression and prognostic value of EGFR family members in OC. There were some limitations to this study that need to be addressed. First, this is an in silico and bioinformatics analysis based on functional genomics using data from several large databases, which may introduce background heterogeneity. To address these issues, we are planning functional verification studies in well designed in vitro and in vivo models in the near future. In addition, the sample size of the study cohort was limited, and a small fraction of the clinical data was missing. As such, larger studies are needed to clarify these findings. Finally, no multivariable analyses were included; therefore, it is impossible to identify any potential association with other important prognostic factors, such as the FIGO stage, patient age, residual tumor after initial surgery, lymph node metastasis, vascular invasion, cancer antigen 125, and Human epididymis protein 4, BRCA, Risk of Malignancy Index II, and Risk of Malignancy Algorithm. Therefore, future research is still needed to address these issues.

Conclusion
==========

In summary, the mRNA expression levels of *ERBB2/3/4* were significantly upregulated, whereas the transcription levels of EGFR were low in patients with OC. Aberrant *EGFR* expression and *ERBB2/3/4* mRNA levels were all found to be associated with the prognosis of OC. These results suggest that *EGFR* and *ERBB 3/4* may be prognostic biomarkers and potential targets for OC. These results may help us better understand the molecular foundations of OC. They may also be useful for the development of tools that can be used for OC prognosis and may help promote the development of *EGFR*-targeted inhibitors for the treatment of OC.
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![The transcription levels of *EGFR* family members in different types of cancers (ONCOMINE).\
**Notes:** The graphic demonstrated the numbers of datasets with statistically significant mRNA overexpression (red) or down-expression (blue) of the target gene. The threshold was designed with following parameters: *P*-value =0.001; fold-change =1.5 and data type, mRNA.\
**Abbreviations:** *EGFR*, epidermal growth factor receptor; *ERBB2*, receptor tyrosine-protein kinase *erbB-2; ERBB3*, receptor tyrosine-protein kinase *erbB-3*; *ErbB4*, receptor tyrosine-protein kinase *erbB-4*.](cmar-10-6937Fig1){#f1-cmar-10-6937}

![The expression of *EGFR* family members and tumor stage in OC patients (*GEPIA*).\
**Notes:** Box plots derived from gene expression data in GEPIA comparing expression of a specific EGFR family member in OC tissue and normal tissues, the *P*-value was set up at 0.05. (**A**) The distribution of *EGFR* mRNA expression; (**B**) the distribution of *ERBB2* mRNA expression; (**C**) the distribution of *ERBB3* mRNA expression; (**D**) the distribution of *ERBB3* mRNA expression between OC tissue and normal tissues; (**E**) correlation between *EGFR* expression and tumor stage; (**F**) correlation between *ERBB2* expression and tumor stage; (**G**) correlation between *ERBB3* expression and tumor stage; (**H**) correlation between *ERBB4* expression and tumor stage in OC patients.\
**Abbreviations:** *EGFR*, epidermal growth factor receptor; *ERBB2*, receptor tyrosine-protein kinase *erbB-2*; *ERBB3*, receptor tyrosine-protein kinase *erbB-3*; *ERBB4*, receptor tyrosine-protein kinase *erbB-4*; OC, ovarian cancer; T, tumor; N, normal.](cmar-10-6937Fig2){#f2-cmar-10-6937}

![The prognostic value of mRNA level of *EGFR* family members in OC patients (Kaplan--Meier plotter).\
**Notes:** The OS, PFS, and PPS survival curve comparing the patient with high (red) and low (black) EGFR family members' expression in OC were plotted from Kaplan--Meier plotter database as the threshold of *P*-value \<0.05, respectively. OS curves of (**A**) *EGFR* (Affymetrix IDs: 1565483_at); (**B**) *ERBB2* (Affymetrix IDs: 210930_s\_at); (**C**) *ERBB3* (Affymetrix IDs: 1563253_s\_at); (**D**) *ERBB4* (Affymetrix IDs: 206794_at). PFS curves of (**E**) *EGFR* (Affymetrix IDs: 1565483_at); (**F**) *ERBB2* (Affymetrix IDs: 210930_s\_at); (**G**) *ERBB3* (Affymetrix IDs: 1563253_s\_at); (**H**) *ERBB4* (Affymetrix IDs: 206794_at). PPS curves of (**I**) *EGFR* (Affymetrix IDs: 1565483_at); (**J**) *ERBB2* (Affymetrix IDs: 210930_s\_at); (**K**) *ERBB3* (Affymetrix IDs: 1563253_s\_at); (**L**) *ERBB4* (Affymetrix IDs: 206794_at).\
**Abbreviations:** *EGFR*, epidermal growth factor receptor; *ERBB2*, receptor tyrosine-protein kinase *erbB-2*; *ERBB3*, receptor tyrosine-protein kinase *erbB-3*; *ERBB4*, receptor tyrosine-protein kinase erbB-4; OS, overall survival; PFS, progression-free survival; PPS, post-progression survival.](cmar-10-6937Fig3){#f3-cmar-10-6937}

![Alteration frequency of *EGFR* familymembers and neighbor genes network in OC (cBioPortal and GeneMANIA).\
**Notes:** (**A**) Summary of alteration in *EGFR* family members. (**B**) OncoPrint visual summary of alteration on a query of *EGFR* family members. (**C**) Kaplan--Meier plots comparing OS in cases with/without *EGFR* family members gene alterations. (**D**) Kaplan--Meier plots comparing disease-free survival (DFS) in cases with/without EGFR family member alterations. (**E**) Gene--gene interaction network among *EGFR* family members.\
**Abbreviations:** *EGFR*, epidermal growth factor receptor; *ERBB2*, receptor tyrosine-protein kinase *erbB-2*; *ERBB3*, receptor tyrosine-protein kinase *erbB-3*; *ERBB4*, receptor tyrosine-protein kinase *erbB-4*; OS, overall survival.](cmar-10-6937Fig4){#f4-cmar-10-6937}

![The *KEGG* pathway enrichment analysis of *EGFR* family members and neighbor genes in OC (DAVID).\
**Notes:** The graphic demonstrated the functions of *EGFR* family and genes significantly associated with EGFR family alterations were predicted by analysis of the KEGG. The length of the X-axis represents −log (*P*-value).\
**Abbreviations:** OC, ovarian cancer; EGFR, epidermal growth factor receptor; KEGG, Kyoto Encyclopedia of Genes and Genomes.](cmar-10-6937Fig5){#f5-cmar-10-6937}

###### 

The transcription levels of *EGFR* family members between different types of OC and normal tissues (ONCOMINE)

  EGFR family members                                    Types of OC vs normal                           Fold change   *t*-Test        *P*-value           Ref               PMID
  ------------------------------------------------------ ----------------------------------------------- ------------- --------------- ------------------- ----------------- ----------
                                                                                                                                                                             
  EGFR                                                   Ovarian serous adenocarcinoma vs normal         −1.223        −1.44           0.906               Adib Ovarian      14760385
  Ovarian serous adenocarcinoma vs normal                −1.349                                          −2.226        0.983           Yoshihara Ovarian   19486012          
  ERBB2                                                  Ovarian endometrioid adenocarcinoma vs normal   1.402         11.344          **2.35E--12**       Hendrix Ovarian   16452189
  Ovarian mucinous adenocarcinoma vs normal              1.47                                            9.83          **3.85E--08**   Hendrix Ovarian     16452189          
  Ovarian serous adenocarcinoma vs normal                1.408                                           13.145        **2.76E--12**   Hendrix Ovarian     16452189          
  Ovarian clear cell adenocarcinoma vs normal            1.826                                           7.306         **5.99E--05**   Hendrix Ovarian     16452189          
  Ovarian serous surface papillary carcinoma vs normal   1.75                                            5.939         **8.97E--05**   Welsh Ovarian       11158614          
  Ovarian serous adenocarcinoma vs normal                1.984                                           4.55          **6.53E--06**   Yoshihara Ovarian   19486012          
  Ovarian carcinoma vs normal                            2.484                                           8.219         **2.85E--06**   Bonome Ovarian      18593951          
  Ovarian clear cell adenocarcinoma vs normal            1.672                                           4.176         **2.00E--03**   Lu Ovarian          15161682          
  ERBB3                                                  Ovarian mucinous adenocarcinoma vs normal       2.355         14.003          **2.04E--09**       Hendrix Ovarian   16452189
  Ovarian clear cell adenocarcinoma vs normal            2.308                                           13.845        **5.07E--08**   Hendrix Ovarian     16452189          
  Ovarian endometrioid adenocarcinoma vs normal          1.897                                           13.296        **3.89E--07**   Hendrix Ovarian     16452189          
  Ovarian serous adenocarcinoma vs normal                1.857                                           13.245        **1.05E--06**   Hendrix Ovarian     16452189          
  Ovarian serous adenocarcinoma vs normal                1.807                                           5.877         **6.89E--04**   Adib Ovarian        14760385          
  Ovarian endometrioid adenocarcinoma vs normal          1.635                                           4.022         **9.14E--04**   Lu Ovarian          15161682          
  Ovarian serous adenocarcinoma vs normal                1.947                                           4.391         **1.07E--04**   Lu Ovarian          15161682          
  Ovarian serous adenocarcinoma vs normal                11.326                                          7.647         **2.03E--06**   Yoshihara Ovarian   19486012          
  ERBB4                                                  Ovarian serous adenocarcinoma vs normal         1.725         13.668          **1.67E--17**       Hendrix Ovarian   16452189
  Ovarian endometrioid adenocarcinoma vs normal          1.465                                           9.503         **5.91E--12**   Hendrix Ovarian     16452189          
  Ovarian clear cell adenocarcinoma vs normal            1.646                                           4.866         **8.73E--04**   Hendrix Ovarian     16452189          

**Notes:** *P*-value was analyzed using the *t*-test. The bold font indicates that the difference was statistically significant between the OC and normal tissue group.

**Abbreviations:** *EGFR*, epidermal growth factor receptor; *ERBB2*, receptor tyrosine-protein kinase *erbB-2; ERBB3*, receptor tyrosine-protein kinase *erbB-3*; *ERBB4*, receptor tyrosine-protein kinase *erbB-4*; OC, ovarian cancer; PMID, PubMed unique identifier; Ref, references.

###### 

The prognostic values of *EGFR* family members in all and different pathological subtypes OC patients (Kaplan--Meier plotter)

  EGFR family     Histology   OS      PFS                                                                     
  --------------- ----------- ------- ------------ ------------ ----------- ------- ------------ ------------ -----------
                                                                                                              
  EGFR            Overall     655     1.23         1.00--1.52   **0.049**   617     1.29         1.05--1.59   **0.017**
  1565483_at      Serous      523     1.31         1.03--1.66   **0.027**   1,104   1.33         1.06--1.67   **0.013**
  Endometrioid    30          --      --           0.260        44          2.01    0.45--8.97   0.350        
  ERBB2           Overall     1,656   0.86         0.74--0.99   **0.041**   1,435   0.88         0.70--1.00   0.057
  210930_s\_at    Serous      1,207   0.80         0.68--0.95   **0.009**   1,104   1.25         1.08--1.45   **0.002**
  Endometrioid    37          0.29    0.03--2.56   0.230        51          0.53    0.19--1.49   0.230        
  ERBB3           Overall     655     0.78         0.62--1.00   **0.046**   614     0.85         0.69--1.04   0.110
  1563253_s\_at   Serous      523     1.22         0.97--1.53   0.084       483     1.26         1.01--1.56   **0.004**
  Endometrioid    30          --      --           0.020        44          2.66    0.44--9.57   0.120        
  ERBB4           Overall     1,656   1.13         0.97--1.31   0.120       1,435   0.83         0.73--0.95   **0.006**
  206794_at       Serous      1,207   1.27         1.07--1.51   **0.006**   1,104   0.88         0.75--1.03   0.110
  Endometrioid    37          0.14    0.02--0.24   **0.039**    51          0.53    0.21--1.34   0.170        

**Notes:** *P*-value was analyzed using the survival analysis test. The bold font indicates that the difference was statistically significant.

**Abbreviations:** *EGFR*, epidermal growth factor receptor; *ERBB2*, receptor tyrosine-protein kinase *erbB-2*; *ERBB3*, receptor tyrosine-protein kinase *erbB-3*; *ERBB4*, receptor tyrosine-protein kinase *erbB-4*; OC, ovarian cancer; OS, overall survival; *PFS*, progression-free survival.

###### 

The prognostic values of *EGFR* family members in OC patients with different clinicopathological features (Kaplan--Meier plotter)

  EGFR family              Clinicopathological features   OS      PFS                                                                          
  ------------------------ ------------------------------ ------- ------------ ---------------- ----------- ------- ------------ ------------- -----------
                                                                                                                                               
  **Pathological grade**                                                                                                                       
                                                                                                                                               
  EGFR                     I                              41      2.71         0.60--12.35      **0.180**   28      3.44         0.43--27.54   0.220
  1565483_at               II                             162     0.78         0.50--1.20       0.250       161     0.78         0.54--1.33    0.190
  III                      392                            1.38    1.07--1.78   **0.013**        315         1.37    1.04--1.81   **0.026**     
  IV                       18                             --      --           --               18          --      --           --            
  ERBB2                    I                              56      0.55         0.19--1.57       0.250       37      0.47         0.15--1.45    0.180
  210930_s\_at             II                             324     1.27         0.94--1.72       0.120       256     1.39         0.99--1.95    0.058
  III                      1,015                          0.79    0.66--0.95   **0.014**        837         1.18    1.00--1.40   0.520         
  IV                       20                             0.6     0.20--1.75   0.340            19          --      --           --            
  ERBB3                    I                              41      0.43         0.14--1.34       0.130       28      2.79         0.35--22.33   0.310
  1563253_s\_at            II                             162     0.52         **0.32--0.85**   **0.008**   161     0.49         0.33--0.71    **0.000**
  III                      392                            0.8     0.59--1.06   0.120            315         1.19    0.92--1.53   0.180         
  IV                       18                             --      --           --               18          --      --           --            
  ERBB4                    I                              56      0.24         0.09--0.65       **0.003**   37      0.33         0.11--1.01    **0.041**
  206794_at                II                             324     1.38         0.96--1.98       0.078       256     1.15         0.82--1.62    0.420
  III                      1,015                          1.26    1.04--1.52   **0.018**        837         0.86    0.71--1.03   0.100         
  IV                       20                             0.42    0.15--1.15   0.081            19          --      --           --            
                                                                                                                                               
  **Clinical stage**                                                                                                                           
                                                                                                                                               
  EGFR                     I+II                           83      2.7          0.61--11.98      0.170       115     0.50         0.23--1.10    0.080
  1565483_at               III + IV                       487     0.87         0.69--1.09       0.230       494     1.30         1.05--1.61    **0.016**
  ERBB2                    I+II                           135     2.86         0.98--8.33       **0.043**   163     0.52         0.27--0.99    **0.042**
  210930_s\_at             III + IV                       1,220   0.88         0.75--1.03       0.099       1,081   1.25         1.07--1.46    **0.005**
  ERBB3                    I+II                           83      0.54         0.19--1.54       0.240       115     0.53         0.25--1.14    0.099
  1563253_s\_at            III + IV                       487     1.15         0.91--1.45       0.230       494     1.12         0.91--1.38    0.260
  ERBB4                    I+II                           135     0.53         0.24--1.16       0.110       163     0.48         0.26--0.89    **0.017**
  206794_at                III + IV                       1,220   0.86         0.74--1.01       0.062       1,081   0.83         0.71--0.97    **0.018**
                                                                                                                                               
  **TP53 mutation**                                                                                                                            
                                                                                                                                               
  EGFR                     mutated                        124     1.33         0.91--1.95       0.130       124     1.59         1.09--2.31    **0.001**
  1565483_at               wild type                      19      --           --               --          19      --           --            --
  ERBB2                    mutated                        506     1.52         1.21--1.91       **0.000**   483     1.55         1.24--1.95    **0.000**
  210930_s\_at             wild type                      94      1.61         0.92--2.81       0.095       84      0.68         0.38--1.19    0.170
  ERBB3                    mutated                        124     1.63         1.07--2.50       **0.023**   124     1.76         1.17--2.66    **0.006**
  1563253_s\_at            wild type                      19      --           --               --          19      --           --            --
  ERBB4                    mutated                        506     1.16         0.90--1.49       0.240       483     0.78         0.61--1.00    **0.047**
  206794_at                wild type                      94      1.32         0.73--2.37       0.360       84      0.70         0.42--1.18    0.180

**Notes:** *P*-value was analyzed using the survival analysis test. The bold font indicates that the difference was statistically significant.

**Abbreviations:** *EGFR*, epidermal growth factor receptor; PFS, progression-free survival; *ERBB3*, receptor tyrosine-protein kinase *erbB-3*; *ERBB2*, receptor tyrosine-protein kinase *erbB-2*; *ERBB4*, receptor tyrosine-protein kinase *erbB-4*; OC, ovarian cancer; OS, overall survival.

###### 

The GO function enrichment analysis of *EGFR* family members and neighbor genes in OC (DAVID)

  Category           Term         Description                                                        Count   *P*-value
  ------------------ ------------ ------------------------------------------------------------------ ------- ---------------
                                                                                                             
  GOTERM_BP_DIRECT   GO:0007169   Transmembrane receptor protein tyrosine kinase signaling pathway   6       **4.85E--08**
  GOTERM_BP_DIRECT   GO:0007173   EGFR signaling pathway                                             5       **2.78E--07**
  GOTERM_BP_DIRECT   GO:0008286   Insulin receptor signaling pathway                                 4       **3.15E--05**
  GOTERM_BP_DIRECT   GO:0008284   Positive regulation of cell proliferation                          6       **4.02E--05**
  GOTERM_BP_DIRECT   GO:0030154   Cell differentiation                                               4       **1.16E--03**
  GOTERM_MF_DIRECT   GO:0004716   Receptor signaling protein tyrosine kinase activity                4       **7.99E--08**
  GOTERM_MF_DIRECT   GO:0005154   EGFR binding                                                       3       **3.87E--05**
  GOTERM_MF_DIRECT   GO:0004714   Transmembrane receptor protein tyrosine kinase activity            3       **2.49E--04**
  GOTERM_MF_DIRECT   GO:0008083   Growth factor activity                                             3       **3.46E--04**
  GOTERM_MF_DIRECT   GO:0046935   1-Phosphatidylinositol-3-kinase regulator activity                 2       **5.60E--03**
  GOTERM_CC_DIRECT   GO:0016323   Basolateral plasma membrane                                        3       **3.56E--03**
  GOTERM_CC_DIRECT   GO:0043235   Receptor complex                                                   3       **3.69E--03**
  GOTERM_CC_DIRECT   GO:0005925   Focal adhesion                                                     4       **1.34E--02**
  GOTERM_CC_DIRECT   GO:0005942   Phosphatidylinositol 3-kinase complex                              2       **2.19E--02**
  GOTERM_CC_DIRECT   GO:0005615   Extracellular space                                                5       **3.03E--02**

**Notes:** The bold font indicates that the difference was statistically significant.

**Abbreviations:** GO, gene ontology; BP, biological process; CC, cellular component; DAVID, Database for Annotation, Visualization and Integrated Discovery; MF, molecular function.
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